A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer.
Breast Cancer
DRUG: 6.0 mg/kg of TQB2102 for injection|DRUG: 7.5 mg/kg of TQB2102 for injection
Total physiological complete response (tpCR), The percentage of the patients where the primary breast lesion shows no residual infiltrating cancer and the regional lymph nodes are negative., Up to 12 months.
Breast pathological complete (bpCR) response, The percentage of the patients where the primary breast lesion shows no residual infiltrating cancer., Up to 12 months.|Objective response rate (ORR), The percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by the investigator based on the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1., Up to 12 months.|Event-free survival (EFS), From randomization to the first time to occurrence of the following events，including disease progression precluding surgery, ipsilateral or contralateral recurrence of invasive breast cancer, regional or distant recurrence of invasive breast cancer, a second primary malignancy in a non-breast site, and death for any reason., Up to 60 months.|Invasive Disease-free survival (IDFS), From randomization to the first time to occurrence of the following events，including ipsilateral or contralateral recurrence of invasive breast cancer, regional or distant recurrence of invasive breast cancer, a second primary malignancy in a non-breast site, and death for any reason., Up to 60 months.|The occurrence rate of all adverse events (AEs), The occurrence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), From the date of signing the informed consent to 28 days after the last dosing or a new anti-tumor treatment, whichever comes first.|The severity of all adverse events (AEs), The severity of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0)., From the date of signing the informed consent to 28 days after the last dosing or a new anti-tumor treatment, whichever comes first.|Anti-drug antibody (ADA), Incidence of anti-drug antibody (ADA), 1 hour Before infusion on Cycle 1 Day1, Cycle 2 Day1, Cycle 4 Day1, Cycle 6 Day1, Cycle 8 Day1, and 90 days after the end of the last infusion. Each cycle is 21 days.
To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer.